Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE vs BENZONATATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
Symptomatic relief of cough
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
100 mg to 200 mg orally three times daily as needed for cough.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Metabolized by plasma esterases (including pseudocholinesterase) to tetracaine and other metabolites.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
Approximately 75–85% bound primarily to albumin.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Approximately 3.5 L/kg, indicating extensive tissue distribution.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
Oral: Estimated 20–30% due to extensive first-pass metabolism.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
No specific dosage adjustment is recommended for renal impairment per manufacturer; however, caution and monitoring are advised.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
No specific dosage adjustment is recommended for hepatic impairment per manufacturer; however, caution is advised.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Safety and efficacy have not been established in children under 10 years of age. For children ≥10 years, adult dosing can be considered.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Elderly patients may be more sensitive to CNS effects; start at lower end of dosing range (100 mg three times daily) and monitor carefully.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Severe allergic reactions (e.g., bronchospasm, laryngospasm, cardiovascular collapse) have been reported, especially with chewing or sucking capsules.,Capsules must be swallowed whole to avoid oral mucosal anesthesia and choking hazard.,Use with caution in patients with hypersensitivity to ester-type local anesthetics.,Safety and efficacy in children <10 years not established.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
Hypersensitivity to benzonatate or related compounds (e.g., tetracaine, procaine)
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
No significant food interactions. The manufacturer does not list any specific dietary restrictions, but alcohol may enhance central nervous system side effects such as drowsiness.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near term. Second and third trimesters: Avoid use due to potential for neonatal apnea and withdrawal; benzonatate is a local anesthetic with CNS depressant effects.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
No data on excretion in human milk; M/P ratio unknown. Benzonatate and its metabolites may be present in breast milk. Caution advised due to potential for infant CNS depression and apnea. Consider benefit of breastfeeding vs risk of drug exposure.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
No pharmacokinetic studies in pregnancy. Dose adjustments not established. Use lowest effective dose if necessary. Avoid in third trimester due to neonatal risk. Increased plasma volume may reduce drug levels, but lack of data prevents formal dose adjustment recommendations.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Benzonatate is a peripherally acting antitussive that anesthetizes stretch receptors in the respiratory tract. Onset of action is within 15-20 minutes and lasts 3-8 hours. Capsules must be swallowed whole; chewing or sucking can cause oropharyngeal anesthesia and choking hazard. Use with caution in patients with a history of drug allergy to tetracaine or other ester-type anesthetics. It is contraindicated in children under 10 years due to increased risk of adverse effects. Overdose can cause seizures, cardiac arrest, and death; treatment is supportive with no specific antidote.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
Swallow the capsule whole; do not chew, suck, or crush it, as this can cause numbness in your mouth or throat and increase risk of choking.,Take the medication exactly as prescribed; do not take more than directed.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Contact your doctor if your cough persists for more than 5 days, or if it is accompanied by fever, rash, or persistent headache.,Keep out of reach of children; accidental ingestion can be fatal in children under 10.,Store at room temperature away from moisture and heat.
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE vs BENZONATATE, answered by our medical review team.
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. BENZONATATE is a Antitussive that works by Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE and BENZONATATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of BENZONATATE is: 100 mg to 200 mg orally three times daily as needed for cough.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE and BENZONATATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . BENZONATATE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near te. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.